Pharma Grapevine: NICE assessment, fame and the blue line
This article was originally published in Scrip
An occasional column in which we report amusing trivialities, pharmalicious gossip, biotech bons mots and other interesting observations picked up on our rounds.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.